How do you address pre-existing anti-MeV immunity in preclinical models?

We employ a multi-pronged strategy: envelope glycoprotein engineering (H/F swapping with morbillivirus homologs or scFv-based retargeting) to ablate recognition by neutralizing antibodies; intratumoral rather than intravenous administration; and the use of cell carriers as Trojan horses for shielded delivery. These strategies are evaluated in MeV-pre-immunized mouse models.

Which MeV vaccine strains are available for cancer vaccine engineering?

Our platform maintains full-length antigenomic cDNA clones for multiple MeV vaccine strains including Edmonston B, Schwarz, Moraten, Zagreb, and the Chinese Hu191 lineage. Each strain has distinct properties. Strain selection is guided by your cancer indication, the tumor's complement of MeV entry receptors (CD46, nectin-4), and the desired balance between oncolytic potency and safety.

Measles Virus-Based Oncolytic Cancer Vaccine Preclinical Design Services

Q: What in vivo tumor models do you support for MeV vaccine efficacy testing?

We support both xenograft and syngeneic models. For direct oncolysis, we use subcutaneous and orthotopic human tumor xenografts in immunodeficient mice. For vaccine-induced immunity, we deploy syngeneic models including B16-F10 melanoma, CT26 colon carcinoma, and 4T1 breast carcinoma in immunocompetent hosts. We also offer bilateral flank tumor models for quantifying abscopal effects and MeV-pre-immunized host models.

Measles Virus-Based Oncolytic Cancer Vaccine Preclinical Design Services

Creative Biolabs delivers a fully integrated preclinical platform for designing and engineering measles virus (MeV)-based vaccines for cancer immunotherapy. MeV vaccine strains—derived from the extensively characterized Edmonston lineage and related attenuated variants—possess a unique combination of features that make them exceptionally suited for oncolytic virotherapy and tumor antigen delivery: a well-documented half-century safety record from over one billion vaccinated individuals, inherent tumor selectivity driven by defects in the antiviral interferon (IFN) pathway, cytoplasmic RNA replication with zero risk of genomic integration, and a versatile reverse genetics system enabling transgene insertion up to 6 kb of additional coding capacity. Our service encompasses the complete preclinical development arc, spanning the two principal MeV-based vaccination strategies—live replicating oncolytic MeV that mediates direct tumor lysis while releasing tumor-associated antigens in situ, and non-replicating or single-cycle MeV vectors engineered to deliver heterologous tumor antigens to professional antigen-presenting cells. From MeV backbone engineering and receptor retargeting through production scale-up, in vitro potency characterization, and in vivo efficacy assessment in syngeneic and xenograft tumor models, our multidisciplinary team provides an end-to-end solution tailored to your cancer indication and translational objectives.

Why Measles Virus? The Built-In Advantages of an Oncolytic Vaccine Platform

MeV: A Paramyxovirus with Unrivaled Safety Credentials

Measles virus is a non-segmented, negative-sense, single-stranded RNA virus of the Paramyxoviridae family. Its 16 kb genome encodes six structural proteins (N, P, M, F, H, L) and two non-structural proteins (C, V). The MeV Edmonston vaccine strain and its derivatives—including Schwarz, Moraten, Zagreb, and CAM-70—have been administered to over one billion people worldwide, establishing the most extensive human safety dataset of any live-attenuated viral platform. Critically, this safety record extends across diverse immunocompromised populations, providing a unique regulatory foundation for cancer-directed applications. MeV enters target cells via three known receptors—CD46 (ubiquitous on nucleated cells, overexpressed in many cancers), SLAM/CD150 (immune cells), and nectin-4/PVRL4 (epithelial cells, frequently upregulated in carcinomas)—creating a natural tropism profile that overlaps significantly with malignant tissue.

Two Vaccine Modalities, One Platform
MeV can be deployed either as a live replicating oncolytic virus that selectively lyses tumor cells while releasing tumor antigens for cross-priming, or as a replication-defective antigen-delivery vector engineered for targeted expression of heterologous tumor-associated or neoantigen cassettes in professional antigen-presenting cells.

Core Preclinical Challenges We Address:
Neutralizing anti-MeV antibodies from prior vaccination limiting systemic delivery.
Engineering MeV envelope glycoproteins (H/F) to retarget tumor-specific receptors.
Balancing oncolytic potency with genetic stability for multi-transgene vectors.
Quantifying MeV-induced immunogenic cell death (ICD) and antigen spread in vivo.

MeV vs. Other Oncolytic Viral Platforms: Where MeV Excels

Key Attribute	Other Oncolytic Viruses (HSV-1, Adenovirus, Vaccinia)	Measles Virus (MeV) Vaccine Strains
Human Safety Record	Limited populations; HSV-1 and VACV can cause disease in immunocompromised.	>1 billion doses; 50-year pediatric vaccination history.
Genomic Integration Risk	Adenovirus: low but theoretical; HSV-1: episomal latency in neurons.	Zero integration risk: cytoplasmic RNA only.
Inherent Tumor Selectivity	Relies heavily on engineered promoters or deletion of virulence genes.	Natural selectivity via IFN-defective tumor pathway.
Transgene Capacity & Stability	HSV-1: ~30 kb (but complex); Adenovirus: ~8 kb (gutless variants larger but harder to produce).	~6 kb additional; highly stable with no recombination.

End-to-End MeV Vaccine Engineering Service Modules

Our preclinical MeV vaccine services are organized into six interconnected modules, each customizable to your cancer antigen targets, viral backbone preferences, and in vivo model requirements. Choose the full pipeline or select individual modules to complement your existing workflow.

Strategy

MeV Backbone & Modality Selection

Strategic evaluation and backbone selection matched to your tumor indication and therapeutic goal.

Strain Screening: Comparative analysis of Edmonston, Schwarz, Moraten, and Hu191 backbones.
Modality Decision: Oncolytic replicating virus vs. replication-defective antigen-delivery vector.
Receptor Strategy: Native tropism exploitation (CD46/SLAM/nectin-4) vs. engineered retargeting.
Biosafety Assessment: Pre-existing immunity profiling and risk stratification for the target indication.

Engineering

Reverse Genetics & Recombinant MeV Construction

Full spectrum genetic engineering using established MeV reverse genetics systems for customized vaccine design.

Full-Length cDNA Cloning: Assembly of MeV antigenomic plasmids with desired modifications.
Transgene Cassette Design: Codon-optimized tumor antigen, cytokine, or reporter gene insertion.
Envelope Engineering: H/F glycoprotein modification for retargeting, stealth, or fusogenic activity tuning.
Virus Rescue: Co-transfection with helper plasmids (N, P, L) in qualified producer cell lines.

Production

MeV Propagation, Purification & Titration

Scalable production of high-titer MeV stocks with rigorous quality control throughout the process.

Cell Substrate Selection: Vero, MRC-5, or tumor cell line-based propagation optimization.
Upstream Process: Multi-step amplification from rescue seed to bulk production harvest.
Downstream Purification: Tangential flow filtration, sucrose cushion, or iodixanol gradient ultracentrifugation.
Titer Determination: TCID50 by limiting dilution on Vero-SLAM cells with syncytium enumeration.

Validation

In Vitro Oncolytic & Expression Validation

Comprehensive characterization of oncolytic potency, transgene expression, and tumor cell tropism.

Cytotoxicity Profiling: MTS/MTS-based viability assays across a panel of cancer cell lines.
Syncytium Quantitation: Imaging-based measurement of MeV F-protein-mediated cell-cell fusion.
Transgene Expression: Flow cytometry and ELISA quantification of encoded antigens or cytokines.
Replication Kinetics: Single-step and multi-step growth curves across permissive and semi-permissive lines.

Immunogenicity

Immunogenicity & ICD Assessment

Multi-parametric evaluation of MeV-induced antitumor immunity and immunogenic cell death markers.

ICD Biomarker Panel: Surface calreticulin, HMGB1 release, ATP secretion, and HSP70/90 exposure.
DC Maturation: Co-culture assays measuring CD80/86 upregulation and IL-12 secretion.
T Cell Priming: Antigen-specific ELISpot and intracellular cytokine staining (IFN-γ, granzyme B).
Innate Activation: Type I IFN, ISG expression, and NK cell activation profiling.

Efficacy

In Vivo Efficacy & Biodistribution

Preclinical tumor model testing with comprehensive pharmacokinetic and pharmacodynamic readouts.

Xenograft Models: Subcutaneous and orthotopic human tumor xenografts in immunodeficient hosts.
Syngeneic Models: Immunocompetent murine tumor models for assessing vaccine-induced immunity.
Biodistribution: qRT-PCR-based tissue viral load quantification and organ tropism mapping.
Survival & Pathology: Kaplan-Meier analysis, tumor-infiltrating lymphocyte (TIL) profiling, and histopathology.

Streamlined MeV Vaccine Preclinical Development Workflow

Integrated MeV vaccine development workflow

Phase 1 — MeV Backbone Selection & Antigen Strategy Design

We begin by evaluating your tumor target profile and selecting the optimal MeV vaccine strain (Edmonston B, Schwarz, Moraten, or Hu191 lineage). The modality choice—live replicating oncolytic MeV vs. replication-defective antigen-delivery vector—is guided by your tumor's CD46/nectin-4 expression status, the host's anti-MeV serostatus, and the desired immune mechanism (direct lysis vs. antigen cross-presentation). At this stage we also design the transgene expression cassette layout, including promoter placement, additional transcription units (ATUs), and co-stimulatory co-expression strategies.

Phase 2 — Reverse Genetics Engineering & Recombinant MeV Construction

Using full-length MeV cDNA plasmids (antigenomic constructs), we insert codon-optimized tumor antigen sequences into designated ATUs positioned between MeV genes. Envelope glycoprotein modifications—including H protein single-chain antibody fusions for receptor retargeting or F protein mutations for enhanced fusogenic activity—are introduced via standard molecular cloning. Recombinant MeV is rescued by co-transfection of the full-length plasmid with N, P, and L helper plasmids into qualified producer cells, followed by passage amplification and clonal selection.

Phase 3 — Virus Amplification, Purification & Quality Release

Rescued MeV clones undergo multi-step amplification in Vero or Vero-SLAM producer cells to achieve target titers (typically 10⁷–10⁸ TCID₅₀/mL). Purification is performed via tangential flow filtration and/or iodixanol gradient ultracentrifugation for removal of cell debris and serum components. Quality release testing includes sterility, endotoxin quantification, transgene sequence confirmation by RT-PCR and Sanger sequencing, and infectious titer determination. Genetic stability after serial passage is verified by whole-genome sequencing.

Phase 4 — In Vitro Oncolytic & Immunogenic Characterization

Purified MeV stocks are tested against a panel of human and murine cancer cell lines representing your target indication. We quantify dose-dependent cytotoxicity (MTS assay), syncytium formation (live-cell imaging), and transgene expression kinetics (flow cytometry at 24, 48, and 72 hours post-infection). Immunogenic cell death is assessed by a multi-parametric panel including surface calreticulin exposure, extracellular HMGB1 ELISA, and ATP luciferase assay. Dendritic cell maturation assays evaluate the capacity of MeV-infected tumor cell lysates to upregulate CD80, CD83, and CD86 on monocyte-derived DCs.

Phase 5 — In Vivo Antitumor Efficacy & Pharmacodynamics

Efficacy is evaluated in both immunodeficient xenograft models (direct oncolysis) and immunocompetent syngeneic models (vaccine-induced immunity). Readouts include tumor volume progression, overall survival, and biodistribution by tissue-specific qRT-PCR. Immune correlates—antigen-specific T cell frequency, cytokine profiles, and TIL composition—are measured longitudinally. For oncolytic MeV constructs, we additionally assess the abscopal effect using bilateral tumor implantation models and evaluate combination potential with immune checkpoint blockade.

Core Enabling Technologies for MeV Vaccine Engineering

MeV Reverse Genetics & Multi-ATU Cassette System

An optimized full-length MeV antigenomic plasmid platform allowing insertion of up to three additional transcription units (ATUs) for simultaneous expression of tumor antigens, co-stimulatory molecules, and reporter genes. The modular design supports rapid exchange of transgene cassettes without re-cloning the backbone, enabling parallel screening of multiple antigen combinations within a single project timeline.

Targeted Envelope Engineering & Stealth Platform

A suite of H and F glycoprotein modification strategies including single-chain antibody (scFv) display, ligand fusion, and morbillivirus glycoprotein swapping (e.g., canine distemper virus envelope exchange). The stealth module incorporates envelope mutations that ablate recognition by pre-existing anti-MeV neutralizing antibodies while preserving fusogenicity, enabling repeated systemic delivery in MeV-immune hosts.

Integrated Oncolytic & Immune Monitoring Platform

A combined assay cascade that simultaneously quantifies direct oncolysis, immunogenic cell death markers (calreticulin, HMGB1, ATP), and downstream immune activation. The platform integrates high-content imaging for syncytium quantitation, multiplexed cytokine profiling, and flow cytometry panels covering DC maturation, T cell activation, and NK cell degranulation—all from parallel aliquots of the same experimental run.

Why Choose Creative Biolabs for MeV Vaccine Development?

Deep MeV Virology & Reverse Genetics Expertise

Our team has hands-on experience with the full spectrum of MeV vaccine strains (Edmonston, Schwarz, Moraten, Hu191) and established reverse genetics protocols for virus rescue, transgene insertion, and envelope retargeting.

Dual-Modality Flexibility: Oncolytic & Vector

Unlike platforms focused on a single modality, we support both live replicating oncolytic MeV and replication-defective antigen-delivery vectors, allowing you to compare strategies head-to-head or combine complementary approaches.

Complete Preclinical Characterization

From viral genome sequence verification through ICD biomarker quantification and in vivo tumor model testing, we deliver a thoroughly characterized MeV vaccine candidate with a comprehensive data package ready for translational decision-making.

Customizable, Modular Service Design

Our six service modules are independently selectable. Whether you need only H/F envelope retargeting for an existing MeV backbone or the full pipeline from antigen design through in vivo efficacy, we adapt to your project stage.

Research Insight: MeV Oncolytic Virotherapy Drives Durable Antitumor Immunity

Key Findings from Preclinical MeV Cancer Vaccine Studies

A growing body of literature underscores the dual value of MeV as both a direct oncolytic agent and a versatile vaccine vector platform. Engineered MeV vaccine strains have demonstrated robust antitumor activity across solid and hematologic malignancies, with evidence of durable immunologic memory.

Comprehensive Oncolytic Mechanism: Engeland and Ungerechts (2021) reviewed the multifaceted antitumor activity of oncolytic MeV, documenting that direct tumor lysis is complemented by MeV-induced immunogenic cell death, which releases damage-associated molecular patterns (DAMPs) and tumor antigens that prime dendritic cells, creating an in situ vaccination effect.¹
Neutralization-Evading MeV Design: Muñoz-Alía et al. (2021) engineered MeV-Stealth, a fully retargeted oncolytic MeV in which the H and F glycoproteins were replaced with CDV counterparts bearing a CD46-specific scFv. This construct resisted neutralization by measles-immune human serum while maintaining potent oncolysis, addressing the central barrier of anti-MeV pre-existing immunity.²
MeV as a Universal Vaccine Platform: Ebenig et al. (2022) systematically characterized the versatility of live-attenuated MeV as a recombinant vaccine vector, demonstrating its capacity to stably accommodate diverse heterologous antigens—from viral glycoproteins to tumor-associated antigens—while inducing robust humoral and cellular immunity, supported by decades of pediatric safety data.³
Oncolytic rMV-Hu191 Triggers Pyroptosis: Wu et al. (2023) demonstrated that the recombinant MeV Hu191 strain exerts a potent oncolytic effect against esophageal squamous cell carcinoma via caspase-3/GSDME-mediated pyroptosis, a highly immunogenic form of cell death that releases pro-inflammatory cytokines and tumor antigens, thereby amplifying the downstream antitumor immune response.⁴

MeV oncolytic virotherapy drives immunogenic cell death and primes antitumor T cell responses.

Fig.1 rMV-Hu191 induces tumor regression in an ESCC xenograft mouse model.^3,5

FAQs Regarding MeV-Based Cancer Vaccine Services

Oncolytic MeV is a fully replication-competent virus that selectively infects, replicates within, and lyses tumor cells—releasing tumor antigens in situ as an "autologous vaccine" effect. MeV-based antigen-delivery vectors are typically replication-defective or single-cycle constructs engineered to express a specific heterologous tumor antigen (e.g., NY-ESO-1, neoantigen peptides) in transduced cells. The oncolytic approach leverages the virus's intrinsic tumor-killing properties, while the vector approach prioritizes precise antigen delivery to professional antigen-presenting cells. We can help you evaluate which modality—or combination—best matches your therapeutic goals.

We employ a multi-pronged strategy: (1) envelope glycoprotein engineering (H/F swapping with morbillivirus homologs or scFv-based retargeting) to ablate recognition by neutralizing antibodies—as validated in the MeV-Stealth approach; (2) intratumoral rather than intravenous administration to bypass systemic neutralization; and (3) the use of cell carriers (e.g., infected mesenchymal stromal cells or monocytes) as Trojan horses for shielded delivery. These strategies are evaluated in MeV-pre-immunized mouse models to confirm in vivo efficacy under realistic serostatus conditions.

Our platform maintains full-length antigenomic cDNA clones for multiple MeV vaccine strains including Edmonston B, Schwarz, Moraten, Zagreb, and the Chinese Hu191 lineage. Each strain has distinct properties—for example, Edmonston B is the most extensively characterized in oncolytic applications, while Hu191 has demonstrated unique caspase-3/GSDME-mediated pyroptosis induction. Strain selection is guided by your cancer indication, the tumor's complement of MeV entry receptors (CD46, nectin-4), and the desired balance between oncolytic potency and safety.

Yes. MeV's genome organization into sequential transcription units separated by conserved gene-start and gene-end signals permits the insertion of additional transcription units (ATUs) at multiple positions. We routinely design constructs carrying up to three ATUs for simultaneous expression of, for example, a tumor antigen, a co-stimulatory molecule (e.g., GM-CSF or CD80), and a reporter gene for non-invasive imaging. Because MeV gene expression follows a 3′-to-5′ transcriptional gradient, we optimize ATU placement to achieve the desired expression stoichiometry among the transgenes.

We support both xenograft and syngeneic models. For evaluating direct oncolysis, we use subcutaneous and orthotopic human tumor xenografts (e.g., A549 lung carcinoma, MCF-7 breast adenocarcinoma, HCT-116 colorectal carcinoma) in immunodeficient mice with intratumoral MeV administration. For assessing vaccine-induced antitumor immunity, we deploy syngeneic models including B16-F10 melanoma, CT26 colon carcinoma, and 4T1 breast carcinoma in immunocompetent hosts. We also offer bilateral flank tumor models for quantifying abscopal effects and MeV-pre-immunized host models for evaluating efficacy under pre-existing anti-MeV serostatus.

Vector based Vaccine Development Solutions

Adenovirus-Based Cancer Vaccine Design

Poxvirus-Based Cancer Vaccine Design

Alphavirus-Based Cancer Vaccine Design

Lentivirus-Based Cancer Vaccine Design

NDV-Based Cancer Vaccine Design

HSV-1-Based Cancer Vaccine Design

Listeria monocytogenes based Vaccine Development

Salmonella based Vaccine Development

Yeast based Vaccine Development

Arenavirus based Vaccine Development

Related Resources

Scientific References

Engeland, Christine E., and Guy Ungerechts. "Measles Virus as an Oncolytic Immunotherapy." Cancers 13.3 (2021): 544.https://doi.org/10.3390/cancers13030544
Muñoz-Alía, Miguel Ángel, et al. "MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum." PLoS Pathogens 17.2 (2021): e1009283.https://doi.org/10.1371/journal.ppat.1009283
Ebenig, Aileen, Mona V. Lange, and Michael D. Mühlebach. "Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines." npj Vaccines 7.1 (2022): 119.https://doi.org/10.1038/s41541-022-00543-4
Wu, Ailing, et al. "Recombinant measles virus vaccine rMV-Hu191 exerts an oncolytic effect on esophageal squamous cell carcinoma via caspase-3/GSDME-mediated pyroptosis." Cell Death Discovery 9.1 (2023): 171.https://doi.org/10.1038/s41420-023-01466-2
All references are distributed under the CC BY 4.0 open access license, without modification.